middle.news
PYC Therapeutics Advances PKD Drug with Dose Escalation and Extension Approval
8:20am on Wednesday 22nd of July, 2026 AEST
•
Biotechnology
Read Story
PYC Therapeutics Advances PKD Drug with Dose Escalation and Extension Approval
8:20am on Wednesday 22nd of July, 2026 AEST
Key Points
Dose escalation to 2.4 mg/kg approved in Phase 1b trial
Open-Label Extension permits up to 24 months continuous dosing
Phase 1a safety data expected in second half 2026
Phase 1b and extension data anticipated in 2027
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
PYC Therapeutics (ASX:PYC)
OPEN ARTICLE